Developer docs
API playgroundTry for free, no card

Search company profiles

Lung Bioengineering

Full company profile

uuid003fil4

Namestring
Lung Bioengineering
Legal namestring
Lung Bioengineering Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Lung Bioengineering Inc. is a wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR) that operates the first and only full-service centralized Ex Vivo Lung Perfusion (EVLP) service centers in the United States. Founded in 2014, the company uses the Toronto EVLP protocol to evaluate and reassess deceased-donor lungs outside the body, enabling transplant centers to utilize marginal donor lungs that might otherwise be discarded. Since its founding, the company has performed over 1,100 EVLP procedures and facilitated 500+ lung transplants through its two dedicated EVLP centers in Silver Spring, Maryland (28,000 ft², six procedure rooms) and Jacksonville, Florida (25,000 ft², three procedure rooms).

The company's core technology platform is the Centralized Lung Evaluation System (CLES), supported by the Case Management Exchange (CMX) cloud-based clinical decision support system and OrganVue software, which together provide transplant physicians with real-time access to EVLP data including high-definition video, bronchoscopy footage, radiographs, and live perfusion monitoring for remote organ viability assessment. In June 2026, the FDA granted premarket approval for the LungFX device, which Lung Bioengineering plans to integrate into its commercial EVLP service in 2027.

Lung Bioengineering operates on an outcome-based revenue model, charging only for cases resulting in lungs accepted for transplant, which minimizes financial risk for transplant center partners. The company targets hospital-based lung transplant programs and organ procurement organizations (OPOs) through a direct enterprise sales relationship model, with 24/7/365 availability via a dedicated referral line. Named customers include Vanderbilt University Medical Center, INOVA Fairfax, and Duke University, among 16 transplant center sites that participated in the pivotal clinical trial. The service addresses the significant gap of approximately 75% of donor lungs currently not utilized due to concerns about viability, logistical constraints, or complexities in the transplant process.

Short descriptiontext

Lung Bioengineering operates the first and only full-service centralized EVLP centers in the United States, providing ex vivo lung perfusion services to lung transplant programs to evaluate and recover marginal donor lungs, as a subsidiary of United Therapeutics Corporation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ex vivo lung perfusion, lung transplant services, centralized EVLP centers, organ procurement support, donor lung assessment
Industry1 code
PRIMARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
NAICS code2 codes
  • Blood and Organ Banks621991
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Medical Laboratories8071
Product category
Ex Vivo Lung Perfusion Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Outcome-Based EVLP Services
TypeManaged Services
Description

Lung Bioengineering charges only for cases resulting in lungs accepted for transplant. This payment model carries minimal financial risk for transplant centers and aligns incentives toward successful organ utilization. The centralized service model allows transplant centers to outsource otherwise cost and resource-intensive in-house EVLP processes.

lungbioengineering.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Infrastructure, Operations, Technology or R&D
Pricing details1 tier
1Outcome-based EVLP service - only charged when lungs are accepted for transplant
ModelOutcome Based/ PerformanceBilling cadencePay-as-you-go
Notes

No upfront charges for procedures that do not result in accepted lungs for transplant. This model is designed to remove barriers to EVLP access and expand the pool of transplantable lungs.

lungbioengineering.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Lung Bioengineering provides centralized ex vivo lung perfusion (EVLP) services that evaluate deceased-donor lungs outside the body to determine transplant suitability and increase donor lung utilization. Services include donor lung procurement coordination, transport logistics, EVLP procedures performed at dedicated centers in Silver Spring, MD and Jacksonville, FL, real-time clinical data sharing via proprietary cloud-based platforms (CMX and OrganVue), and 24/7/365 clinical specialist support. The outcome-based pricing model charges only for cases resulting in lungs accepted for transplant, removing financial risk for transplant centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 20% increase in transplant volume observed by partner program
+2 more records
Product overview1 text field

Lung Bioengineering is a subsidiary of United Therapeutics Corporation (founded 1996, public benefit corporation since 2021), established in 2014 as the first and only full-service EVLP provider in the United States. The company operates a centralized EVLP service model built on its proprietary Centralized Lung Evaluation System (CLES) platform, using the Toronto EVLP protocol. Its core product is the ex vivo lung perfusion (EVLP) service, which evaluates deceased-donor lungs outside the body to determine transplant suitability and increase organ utilization. The service integrates two key software components: the Case Management Exchange (CMX), a cloud-based clinical decision support system providing real-time EVLP data including high-definition video and bronchoscopy to transplant physicians for remote assessment, and the OrganVue software for data management. Lung Bioengineering maintains two dedicated EVLP centers (Silver Spring, MD and Jacksonville, FL) with combined nine procedure rooms, staffed by LBE Clinical Specialists available 24/7/365. The company recently added the FDA-approved LungFX device (premarket approval June 2026) to its service portfolio, expected to be commercially available via its EVLP service in 2027.

Product and service5 records
1Ex Vivo Lung Perfusion (EVLP) Services
2Case Management Exchange (CMX)
3OrganVue
4Centralized Lung Evaluation System (CLES)
5LungFX
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

United Therapeutics founded Lung Bioengineering as a subsidiary in 2014 to be a leading provider of EVLP services. United Therapeutics is a public benefit corporation (since 2021) focused on developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Lung Bioengineering operates as part of United Therapeutics' mission to transform transplantation.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1TransMedics Group
TypeDirect peer
Description

Publicly traded (NASDAQ: TMDX) organ preservation company offering the Organ Care System for heart, lung, and liver. Directly comparable as a commercial organ perfusion platform with overlapping customer base of transplant centers and OPOs.

TypeEmerging player
Description

Developer of the metra normothermic liver perfusion system. Comparable as an organ preservation technology company targeting transplant centers with similar clinical and economic value propositions around increasing transplantable organ utilization.

TypeEmerging player
Description

Developer of hypothermic organ preservation and transport devices for heart, lung, liver, and kidney. Comparable as an organ preservation company addressing similar transplant center and OPO customers with complementary (not identical) technology.

TypeDirect peer
Description

Swedish-based developer of the XPS™ with STEEN Solution™ Perfusate, the most widely adopted EVLP technology referenced in Lung Bioengineering's own materials. Directly comparable as the primary competing EVLP platform, with FDA-approved indications for donor lung assessment.

TypeBroad incumbent
Description

Parent company of Lung Bioengineering (NASDAQ: UTHR), developer of the LungFX device and broader portfolio of transplant and pulmonary pharmaceuticals. Comparable as the strategic parent and technology licensor with overlapping mission in lung transplantation.

TypeEmerging player
Description

Emerging developer of normothermic organ perfusion devices targeting ex vivo organ repair and assessment. Comparable as an emerging EVLP-style platform company addressing transplant center demand for marginal organ evaluation.

TypeBroad incumbent
Description

Established provider of LifePort hypothermic organ preservation systems used by transplant centers and OPOs. Comparable as a long-standing organ preservation vendor operating in similar procurement workflows.

TypeRegional player
Description

Provider of organ preservation solutions and devices, with strong international and European presence. Comparable as an organ preservation supplier serving similar end customers across transplant programs.

TypeOthers
Description

Medical device company with adjacent focus on vascular and structural heart technologies. Thematically adjacent as a small-cap medical device company addressing similar hospital and procedural specialist customers.

10Institut Georges Lopez (IGL)
TypeOthers
Description

Manufacturer of preservation solutions and devices used in organ transplantation. Comparable as a supplier of complementary inputs to the same transplant programs and OPOs served by Lung Bioengineering.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lung Bioengineering

Ex Vivo Lung Perfusion Serviceslungbioengineering.com

Lung Bioengineering operates the first and only full-service centralized EVLP centers in the United States, providing ex vivo lung perfusion services to lung transplant programs to evaluate and recover marginal donor lungs, as a subsidiary of United Therapeutics Corporation.

What Lung Bioengineering does

Lung Bioengineering Inc. is a wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR) that operates the first and only full-service centralized Ex Vivo Lung Perfusion (EVLP) service centers in the United States. Founded in 2014, the company uses the Toronto EVLP protocol to evaluate and reassess deceased-donor lungs outside the body, enabling transplant centers to utilize marginal donor lungs that might otherwise be discarded. Since its founding, the company has performed over 1,100 EVLP procedures and facilitated 500+ lung transplants through its two dedicated EVLP centers in Silver Spring, Maryland (28,000 ft², six procedure rooms) and Jacksonville, Florida (25,000 ft², three procedure rooms).

The company's core technology platform is the Centralized Lung Evaluation System (CLES), supported by the Case Management Exchange (CMX) cloud-based clinical decision support system and OrganVue software, which together provide transplant physicians with real-time access to EVLP data including high-definition video, bronchoscopy footage, radiographs, and live perfusion monitoring for remote organ viability assessment. In June 2026, the FDA granted premarket approval for the LungFX device, which Lung Bioengineering plans to integrate into its commercial EVLP service in 2027.

Lung Bioengineering operates on an outcome-based revenue model, charging only for cases resulting in lungs accepted for transplant, which minimizes financial risk for transplant center partners. The company targets hospital-based lung transplant programs and organ procurement organizations (OPOs) through a direct enterprise sales relationship model, with 24/7/365 availability via a dedicated referral line. Named customers include Vanderbilt University Medical Center, INOVA Fairfax, and Duke University, among 16 transplant center sites that participated in the pivotal clinical trial. The service addresses the significant gap of approximately 75% of donor lungs currently not utilized due to concerns about viability, logistical constraints, or complexities in the transplant process.

Lung Bioengineering firmographics

Firmographics
Name
Lung Bioengineering
Legal name
Lung Bioengineering Inc.
Website
https://lungbioengineering.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Lung Bioengineering operates the first and only full-service centralized EVLP centers in the United States, providing ex vivo lung perfusion services to lung transplant programs to evaluate and recover marginal donor lungs, as a subsidiary of United Therapeutics Corporation.
Ownership category
akta.pro rank

Lung Bioengineering industry classification

Industry
Product category
Ex Vivo Lung Perfusion Services
NAICS
Blood and Organ Banks (621991), Medical and Diagnostic Laboratories (6215)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management

Keywords

  • Ex vivo lung perfusion
  • Lung transplant services
  • Centralized EVLP centers
  • Organ procurement support
  • Donor lung assessment

Lung Bioengineering business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D

Revenue model

  1. Outcome-Based EVLP Services: Lung Bioengineering charges only for cases resulting in lungs accepted for transplant. This payment model carries minimal financial risk for transplant centers and aligns incentives toward successful organ utilization. The centralized service model allows transplant centers to outsource otherwise cost and resource-intensive in-house EVLP processes.

Pricing tiers

ModelBillingPrice
Outcome Based/ PerformancePay-as-you-goOutcome-based EVLP service - only charged when lungs are accepted for transplant

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Lung Bioengineering product offering

Product offering

Core offering

Lung Bioengineering provides centralized ex vivo lung perfusion (EVLP) services that evaluate deceased-donor lungs outside the body to determine transplant suitability and increase donor lung utilization. Services include donor lung procurement coordination, transport logistics, EVLP procedures performed at dedicated centers in Silver Spring, MD and Jacksonville, FL, real-time clinical data sharing via proprietary cloud-based platforms (CMX and OrganVue), and 24/7/365 clinical specialist support. The outcome-based pricing model charges only for cases resulting in lungs accepted for transplant, removing financial risk for transplant centers.

Product overview

Lung Bioengineering is a subsidiary of United Therapeutics Corporation (founded 1996, public benefit corporation since 2021), established in 2014 as the first and only full-service EVLP provider in the United States. The company operates a centralized EVLP service model built on its proprietary Centralized Lung Evaluation System (CLES) platform, using the Toronto EVLP protocol. Its core product is the ex vivo lung perfusion (EVLP) service, which evaluates deceased-donor lungs outside the body to determine transplant suitability and increase organ utilization. The service integrates two key software components: the Case Management Exchange (CMX), a cloud-based clinical decision support system providing real-time EVLP data including high-definition video and bronchoscopy to transplant physicians for remote assessment, and the OrganVue software for data management. Lung Bioengineering maintains two dedicated EVLP centers (Silver Spring, MD and Jacksonville, FL) with combined nine procedure rooms, staffed by LBE Clinical Specialists available 24/7/365. The company recently added the FDA-approved LungFX device (premarket approval June 2026) to its service portfolio, expected to be commercially available via its EVLP service in 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ex Vivo Lung Perfusion (EVLP) Services
  • Case Management Exchange (CMX)
  • OrganVue
  • Centralized Lung Evaluation System (CLES)
  • LungFX

Quantifiable outcome

  • 20% increase in transplant volume observed by partner program
  • +2 more outcomes

Companies that use Lung Bioengineering

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Lung Bioengineering technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Lung Bioengineering partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • United Therapeutics CorporationcoreStrategic or Co-development Partner · 1 January 2014United Therapeutics founded Lung Bioengineering as a subsidiary in 2014 to be a leading provider of EVLP services. United Therapeutics is a public benefit corporation (since 2021) focused on developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Lung Bioengineering operates as part of United Therapeutics' mission to transform transplantation.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Lung Bioengineering competitors and assessment

Company assessment

Direct peers

  • TransMedics Group: Publicly traded (NASDAQ: TMDX) organ preservation company offering the Organ Care System for heart, lung, and liver. Directly comparable as a commercial organ perfusion platform with overlapping customer base of transplant centers and OPOs.
  • XVIVO Perfusion: Swedish-based developer of the XPS™ with STEEN Solution™ Perfusate, the most widely adopted EVLP technology referenced in Lung Bioengineering's own materials. Directly comparable as the primary competing EVLP platform, with FDA-approved indications for donor lung assessment.

Emerging players

  • OrganOx: Developer of the metra normothermic liver perfusion system. Comparable as an organ preservation technology company targeting transplant centers with similar clinical and economic value propositions around increasing transplantable organ utilization.
  • Paragonix Technologies: Developer of hypothermic organ preservation and transport devices for heart, lung, liver, and kidney. Comparable as an organ preservation company addressing similar transplant center and OPO customers with complementary (not identical) technology.
  • Tevosol: Emerging developer of normothermic organ perfusion devices targeting ex vivo organ repair and assessment. Comparable as an emerging EVLP-style platform company addressing transplant center demand for marginal organ evaluation.

Broad incumbents

  • United Therapeutics Corporation: Parent company of Lung Bioengineering (NASDAQ: UTHR), developer of the LungFX device and broader portfolio of transplant and pulmonary pharmaceuticals. Comparable as the strategic parent and technology licensor with overlapping mission in lung transplantation.
  • Organ Recovery Systems: Established provider of LifePort hypothermic organ preservation systems used by transplant centers and OPOs. Comparable as a long-standing organ preservation vendor operating in similar procurement workflows.

Regional players

  • Bridge to Life: Provider of organ preservation solutions and devices, with strong international and European presence. Comparable as an organ preservation supplier serving similar end customers across transplant programs.

Others

  • InspireMD: Medical device company with adjacent focus on vascular and structural heart technologies. Thematically adjacent as a small-cap medical device company addressing similar hospital and procedural specialist customers.
  • Institut Georges Lopez (IGL): Manufacturer of preservation solutions and devices used in organ transplantation. Comparable as a supplier of complementary inputs to the same transplant programs and OPOs served by Lung Bioengineering.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Lung Bioengineering financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lung Bioengineering leadership team

Management profile

Number of profiles

Profiles1 record

Lung Bioengineering funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lung Bioengineering M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lung Bioengineering

What does Lung Bioengineering do?

Lung Bioengineering provides centralized ex vivo lung perfusion (EVLP) services that evaluate deceased-donor lungs outside the body to determine transplant suitability and increase donor lung utilization. Services include donor lung procurement coordination, transport logistics, EVLP procedures performed at dedicated centers in Silver Spring, MD and Jacksonville, FL, real-time clinical data sharing via proprietary cloud-based platforms (CMX and OrganVue), and 24/7/365 clinical specialist support. The outcome-based pricing model charges only for cases resulting in lungs accepted for transplant, removing financial risk for transplant centers.

Is Lung Bioengineering a public or private company?

Lung Bioengineering is a private company. It is classified as corporate owned and is currently operating.

When was Lung Bioengineering founded?

Lung Bioengineering was founded in 2014. It employs 11 to 50 people.

How does Lung Bioengineering make money?

One revenue line is on record: outcome-Based EVLP Services.

Who are Lung Bioengineering's main competitors?

Direct peers on record are TransMedics Group and XVIVO Perfusion. Emerging players are OrganOx, Paragonix Technologies and Tevosol. Broad incumbents are United Therapeutics Corporation and Organ Recovery Systems. Bridge to Life is listed as a regional player. Others are InspireMD and Institut Georges Lopez (IGL).

Does Lung Bioengineering have an API?

No public API is recorded for Lung Bioengineering.

What industry is Lung Bioengineering in?

Lung Bioengineering's product category is Ex Vivo Lung Perfusion Services. Its primary akta.pro industry code is HLAKANAM, Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management. Its NAICS code is 621991 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales